Assertio (ASRT) Q4 2025 earnings summary

Executive summary

• Leadership transition in October 2025 brought renewed focus on ROLVEDON as the core growth asset and a shift away from broad specialty product acquisitions, emphasizing disciplined capital allocation and leveraging existing commercial capabilities.

• Integration of ROLVEDON completed in Q4 2025, positioning it for commercial success and operational efficiency.

• Commercial infrastructure is now optimized for oncology, with a disciplined approach to capital allocation and business development.

• FY2025 net product sales and adjusted EBITDA exceeded guidance, driven by strong performance in core assets.

Financial highlights

• FY2025 net product sales reached $117.1M, with ROLVEDON contributing $68.2M (up from $60.1M in 2024), Sympazan sales up to $11.3M, and Indocin sales down to $18.9M due to generic competition.

• Q4 2025 total product sales were $12.8M, down from $29.6M in Q4 2024, due to timing of ROLVEDON channel inventory.

• Gross margin improved to 75% in Q4 (from 61%); full-year gross margin was 70% (up from 68%).

• Adjusted EBITDA for FY2025 was $22.7M (up from $18.3M in 2024); Q4 adjusted EBITDA was -$4.1M (vs. $3.4M positive prior year).

• Cash and equivalents at year-end were $63.4M, down from $100.1M at year-end 2024, reflecting working capital changes and divestment cash transfer.

Outlook and guidance

• FY2026 net product sales expected between $110M–$125M and adjusted EBITDA between $28M–$40M.

• ROLVEDON expected to drive growth, with regular sales of newly labeled product to begin Q2 2026 and continued leadership in Medicare Part B clinic market share.

• No expected channel inventory build in 2026; shipments to align with demand.

• Long-term ROLVEDON sales potential seen above $100M annually, with optimism for $100M–$130M and beyond.